ClinicalTrials.gg
Not yet recruitingNCT06315465Updated Mar 18, 2024

Efficacy of MAD as add-on Therapy in Comparison With Standard of Care in Children With ASD

A Phase 2/3 interventional study of Modified Atkin's Diet with standard of care and Standard of Care in Modified Atkins Diet, Autism Spectrum Disorder and Standard of Care, sponsored by All India Institute of Medical Sciences, New Delhi. Not yet recruiting. Open to participants aged 3 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by All India Institute of Medical Sciences, New Delhi · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
3 Years to 8 Years
Sex
All
01

Study summary

In general ketogenic diet is a recognized as an efficient non pharmacological treatment for children with refractory epilepsy. However, in the last decade, it has been tried for many neurological disorders in children including ASD, neurodegenerative disorders.

Studies have shown that KD also helps in improvement of cognition, social skills, language function, and stereotypies. There is a limited number of reports of improvements after KD treatment, was insufficient evidence to attest the practicability of the KD as a treatment for ASD, but it is still a good indicator that this diet is a promising therapeutic option for this disorder. There are no major RCT's, hence raises concerns about the reliability and generalizability of findings. Majority of studies have used combined ketogenic diet therapy rather than single diet therapy and not many studies have compared add-on dietary intervention with standard of care. When compared to classic KD diet Modified Atkin's Diet is less restrictive, more palatable, more feasible and early response can be achieved. In summary, the rationale for conducting this study lies in the importance of add on dietary therapy in form of Modified Atkin's Diet along with standard of care for improvement of behavioral symptoms in children with ASD aged 3-8 years.

This study aims to provide valuable insights that it can improve behavioral symptoms in ASD, early and ultimately improve the developmental outcomes in these children.

Read the detailed description
  • All the children presenting to Paediatrics OPD and Autism clinic in the Child Neurology division will be screened and those fulfilling the inclusion and exclusion criteria will be enrolled into the study
  • Informed consent will be taken from parents for the study
  • Baseline demographic details and following evaluation will be done -

    1. Autism severity assessment using CARS -2, ABC
    2. Neurocognitive assessment using (DQ/IQ/SQ) -VSMS
    3. Behavioral assessment using CBCL
    4. Sleep related issues using CSHQ After initial assessment children are randomized into Group I and Group II using computer generated random numbers.

Group I-Modified Atkin's Diet with standard of care arm

  • Group I will receive Modified Atkin's Diet with standard of care whereas Group II will receive standard of care alone.
  • Children randomized into Group I, initial workup for Modified Atkin's Diet will be done in the form of Electrocardiogram, Renal Function Tests, Liver Function Tests, Complete Blood Counts, Lipid profile, Urine calcium creatinine ratio and Ultrasound Pelvis for nephrocalcinosis. If pre KD work up is normal, then Modified Atkin's Diet will be initiated in the ratio of 1:1.
  • Urine ketones will be checked daily using ketone dipsticks
  • Telephonic contacts will be made in regular intervals every week to further ensure compliance at home, and to ensure proper understanding and confidence of parents
  • Those children who are unable to tolerate taking adequate ketogenic diet therapy requiring discontinuation of therapy, will be considered as deviates
  • First follow-up will be at 4 weeks of treatment initiation, followed by at 8, 12, 16, 20 and 24 weeks
  • Compliance rate and adverse events will also be calculated from patient diary/log
  • Those children who are unable to tolerate taking adequate ketogenic diet therapy requiring discontinuation of therapy, will be considered as deviates
  • First follow-up will be at 4 weeks of treatment initiation, followed by at 8, 12, 16, 20 and 24 weeks
  • Compliance rate and adverse events will also be calculated from patient diary/log
  • Every alternate subject from each category, pre - intervention f MRI and 3 months post intervention f MRI is done (total 10 subjects) Group II -Standard of care arm
  • Standard of care intervention plan will be devised for each subject based on the principles of -
  • Behavioral therapy

    1. Behavioral modification techniques
    2. Psycho education
    3. Cognitive behavioral therapy
    4. Activity based interventions like eye contact exercises, attention enhancement exercises, self-help skills
    5. Speech therapy
    6. Parental training
  • Occupational therapy
  • Sensory integration therapy
  • Pharmacotherapy - Anti-psychotic medications
  • The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioural intervention to be provided to the child.
  • Physical follow up - 4, 8, 12, 16, 20, 24 weeks
  • Follow up assessments - 12 weeks (3 months) \& 24 weeks (6 months)

Functional MRI acquisition Every 4th subject from each group who provide consent for doing a f-MRI, will undergo a pre-intervention f-MRI and post-intervention f-MRI at 3 months follow-up (10 subjects in each arm, i.e. 20 subjects) These investigations would be done free of cost for the patients. The data will be compared with fMRI data of controls (retrospective data of children with dyslexia who received AI enabled-remedial intervention alone (for 6 weeks) as a part of a previous study by Dr Sayoni Roy Chowdhary, under the guidance of Prof Sheffali Gulati as Chief guide, after ethical clearance). The data will also be compared with the historical data of typical readers, acquired using the same f-MRI protocol at our center

02

Conditions studied

  • Modified Atkins Diet
  • Autism Spectrum Disorder
  • Standard of Care

Keywords

  • Modified Atkin's Diet
  • Autism Spectrum Disorder
  • Standard of care
03

In context

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

This study's planned enrollment of 80 is above the median of 52 across 1,374 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

All India Institute of Medical Sciences, New Delhi is the lead sponsor of 143 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Children aged 3 to 8 years diagnosed with Autism Spectrum Disorder according to DSM -V criteria

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed genetic and metabolic syndromes
  2. Pre-existing food fads
  3. Associated seizure disorder/epilepsy syndrome
  4. Chronic systemic illness
  5. Received any form of dietary therapy in the previous 6 months
  6. Not on stable standard of care therapy or changes in antipsychotic medications over the last 1 month
  7. Refusal of consent
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Modified Atkin's diet with standard of care arm

    Group I will receive Modified Atkin's Diet with standard of care whereas Group II will receive standard of care alone. Children randomized into Group I, initial workup for Modified Atkin's Diet will be done in the form of Electrocardiogram, Renal Function Tests, Liver Function Tests, Complete Blood Counts, Lipid profile, Urine calcium creatinine ratio and Ultrasound Pelvis for nephrocalcinosis. If pre KD work up is normal, then Modified Atkin's Diet will be initiated in the ratio of 1:1.Urine ketones will be checked daily using ketone dipsticks. Telephonic contacts will be made in regular intervals every week to further ensure compliance at home, and to ensure proper understanding and confidence of parents. Those children who are unable to tolerate taking adequate ketogenic diet therapy requiring discontinuation of therapy, will be considered as deviates. First follow-up will be at 4 weeks of treatment initiation, followed by at 8, 12, 16, 20 and 24 weeks.

    Dietary Supplement: Modified Atkin's Diet with standard of care · Other: Standard of Care

  • Other
    Standard of care arm

    * Standard of care intervention plan will be devised for each subject based on the principles of - * Behavioral therapy 1. Behavioral modification techniques 2. Psycho education 3. Cognitive behavioral therapy 4. Activity based interventions like eye contact exercises, attention enhancement exercises, self-help skills 5. Speech therapy 6. Parental training * Occupational therapy * Sensory integration therapy * Pharmacotherapy - Anti-psychotic medications * The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioural intervention to be provided to the child. * Physical follow up - 4, 8, 12, 16, 20, 24 weeks * Follow up assessments - 12 weeks (3 months) \& 24 weeks (6 months)

    Other: Standard of Care

Interventions

  • Dietary supplementModified Atkin's Diet with standard of care

    children who have given their consent and are randomized into Group I arm receives Modified Atkins Diet along with standard of care after completion of baseline investigations. Modified Atkin's Diet will be started in ratio of 1:1 and compliance is monitored by urine ketones. Followup will be done telephonically to check for compliance , adverse events at every 4 week intervals till 24 weeks.

  • OtherStandard of Care

    Standard of care intervention plan will be devised for each subject which includes Behavioral therapy , Psychoeducation, Activity based interventions like attention enhancement exercises, self help skills, Occupational therapy, Pharmacotherapy, Sensory integration therapy. The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioral intervention to be provided to the child. Physical follow up will be done every 4 weekly till 24 weeks.

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of add-on Modified Atkin's Diet therapy with standard of care as compared to standard of care alone in children with Autism Spectrum Disorder aged 3-8 years

    Proportion of children with minimum significant reduction of Childhood Autism Rating Scale (CARS-2) score (defined by ≥ 4.5 reduction) in both arms. Childhood Autism Rating Scale is an evaluation tool used for identifying autism and determining the severity of autism spectrum disorder. It can be used in children 2 years and older with Autism Spectrum Disorder. It contains total 15 domains and each domain have score from 0-4. Total score 15 to 60 and total score of less than 30 indicates non autism, 30-36.5 indicates mild to moderate autism, 37-60 is considered as severe autism

    Time frame: 3 months

Secondary outcomes

  1. To evaluate the efficacy of add-on Modified Atkin's Diet therapy with standard of care as compared to standard of care alone in children with Autism Spectrum Disorder aged 3-8 years

    Proportion of children with minimum significant reduction of Childhood Autism Rating Scale (CARS-2) score (defined by ≥ 4.5 reduction) in both arms. Childhood Autism Rating Scale is an evaluation tool used for identifying autism and determining the severity of autism spectrum disorder. It can be used in children 2 years and older with Autism Spectrum Disorder. It contains total 15 domains and each domain have score from 0-4. Total score 15 to 60 and total score of less than 30 indicates non autism, 30-36.5 indicates mild to moderate autism, 37-60 is considered as severe autism

    Time frame: 6 months

  2. To compare the change in the cognitive ability as measured by Developmental Quotient(DQ)in children receiving Modified Atkin's Diet with standard of care vs standard of care alone in children with Autism Spectrum disorder aged 3-8 years.

    Developmental Quotient is assessed in both arms pre and post diet therapy using Developmental profile -3 (DP-3).It utilizes input from parents or caregivers to provide scores in five areas of development: physical, adaptive behavior, social emotional , cognitive, and communication. It provide five scales each with 34 to 38 items, designed to assess the development and functioning of children from birth through age12. Scores less than 70 is considered delayed, 70-84 is considered below average,85-115 is considered average, 116-130 is considered above average and more than 130 is considered well above average.

    Time frame: 6 months

  3. To compare the change in the cognitive ability as measured by Social Quotient(SQ)in children receiving Modified Atkin's Diet with standard of care vs standard of care alone in children with Autism Spectrum disorder aged 3-8 years.

    Social Quotient (SQ) is assessed in both arms pre and post therapy using Vineland Social Maturity Scale. It is generally used to determine three related but different aspects, which is 1)social and adaptive functions,2)level of disability, 3) intelligence. It contains 89 items in 8 domains and assess from 0 to 15 years. Scores of less than 70 is considered as intellectual disability, 70-79 as borderline impaired or delayed, 80-89 is considered as low average, 90-109 is considered as average,110-119 is considered as high average.

    Time frame: 6 months

  4. To compare the change in the cognitive ability as measured by Intelligence Quotient(IQ)in children receiving Modified Atkin's Diet with standard of care vs standard of care alone in children with Autism Spectrum disorder aged 3-8 years.

    Intelligence Quotient (IQ)is assessed in both arms pre and post therapy using Malins Intelligence Scale for Indian children (MISC). It includes both verbal and performance scales. Total 11 subtests are used of which 6 are verbal tests and 5 are performance tests. This test yields three scores: verbal IQ, performance IQ, and full scale IQ scores. Scores of less than 70 is considered as Intellectual disability, 70-79 as borderline impaired or delayed, 80-89 is considered as low average, 90-109 is considered as average,110-119 is considered as high average.

    Time frame: 6 months

  5. To compare the quantitative reduction in behavioral problems using Child Behavior Checklist (CBCL) in children receiving Modified Atkin's Diet with standard of care vs standard of care alone in children with Autism Spectrum Disorder aged 3-8 years.

    Behavior problems like inattention, hyperactivity, aggression are assessed pre and post therapy in both arms using Child Behavior Checklist. This checklist can assess behavior in the following profiles: Anxious/depressed, withdrawn, sleep problems, somatic problems, aggressive behavior, or destructive behavior. Based on these three scores are generated, Total score, Externalizing problem scale , and Internalizing problem scale. Any score that falls below the 93rd percentile is considered normal, scores between the 93-97th percentile are borderline clinical, and any score above the 97th percentile are in the clinical range.

    Time frame: 6 months

  6. To compare the change in sleep related problems using Children's Sleep Habit Questionnaire (CSHQ)children receiving Modified Atkin's Diet with standard of care vs standard of care alone in children with Autism Spectrum Disorder age

    The CSHQ is a parent-rated questionnaire comprised of 45 items; 33 scored questions, and 7 additional items intended to provide other relevant information pertaining to sleep behavior (e.g., nocturnal body pains) Each scored question is rated on a 3-point scale as occurring "usually" (i.e., 5-7 times within the past week), "sometimes" (i.e., 2-4 times within the past week), or "rarely" (i.e., never or 1 time within the past week).A number of items on the questionnaire are reverse-scored, so that higher scores consistently indicate problem behaviors. Ratings are combined to form eight subscales: Bedtime Resistance, Sleep Onset Delay, Sleep Duration, Sleep Anxiety, Night wakings, Parasomnias, Sleep Disordered Breathing, and Daytime Sleepiness. A Total Sleep Disturbances score is calculated as the sum of all CSHQ scored questions, and can range from 33 to 99

    Time frame: 6 months

  7. To compare the resting state fMRI findings in a subset of patients in the two arms

    To observe the changes in resting state functional MRI in both arms (pre and post therapy) at 6 months

    Time frame: 6 months

  8. To assess the compliance in children with Autism Spectrum Disorder receiving add-on Modified Atkin's Diet with standard of care

    compliance will be monitored using Compliance diary

    Time frame: 6 months

  9. To assess the adverse effect profile in children with Autism Spectrum Disorder receiving add-on Modified Atkin's Diet with standard of care

    adverse effects will be checked by Patient diet log

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2024; primary completion for Jan 2026, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Mar 18, 2024
StartEst.
Mar 20, 2024
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jan 1, 2026
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06315465
Responsible party
Sheffali Gulati (Professor, All India Institute of Medical Sciences, New Delhi) — Principal investigator
First posted
Mar 18, 2024
Start date
Mar 20, 2024 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Mar 18, 2024

Study contacts

Sheffali Gulati, MD
Contact
sheffaligulati@gmail.com
01126594679
Sheffali Gulati, MD
Contact
sheffaligulati1@gmail.com
9810386847
Sheffali Gulati, MD
principal investigator · All India Institute of Medical Sciences, New Delhi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion